Search

Displaying results 3481 - 3490 of 8010 in total
  1. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.

  2. Drug

    Phenprocoumon

    go.drugbank.com/drugs/DB00946
    ApprovedInvestigationalWithdrawn

    Coumarin derivative that acts as a long-acting oral anticoagulant.

    Categories: Vitamin K Inhibitors, Vitamin K Antagonists
  3. Drug

    Travoprost

    go.drugbank.com/drugs/DB00287
    ApprovedInvestigational

    Unlike other prostaglandin analogues, travoprost demonstrates full agonism and high selectivity at the prostanoid receptor, reporting a higher efficacy in reducing intraocular pressure and a reduced risk for

  4. Drug

    Alfimeprase

    go.drugbank.com/drugs/DB04919
    Investigational

    Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>). … Alfimeprase is being developed by Nuvelo.

  5. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    Camazepam is a benzodiazepine which is a dimethyl carbamate ester of tamzepam, a metabolite of diazepam. Similarly to other drugs in its class, it has antxiolytic, anticonvulsant, hypnotic, and skeletal muscle relaxant properties. Howeve...

  6. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. … As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension

    Categories: Antihistamines for Systemic Use
  7. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  8. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418] … [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

    Categories: Antiinfectives for Systemic Use
  9. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia. … Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2. … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination

    Categories: Experimental Unapproved Treatments for COVID-19